Beihai Gofar Chuanshan Biological Co., Ltd. Logo

Beihai Gofar Chuanshan Biological Co., Ltd.

600538.SS

(0.8)
Stock Price

4,06 CNY

-10.91% ROA

-10.09% ROE

-22.82x PER

Market Cap.

2.023.404.280,00 CNY

2.84% DER

0% Yield

-25.28% NPM

Beihai Gofar Chuanshan Biological Co., Ltd. Stock Analysis

Beihai Gofar Chuanshan Biological Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Beihai Gofar Chuanshan Biological Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.58x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

The stock's ROE indicates a negative return (-1.4%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-1.59%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-226) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Beihai Gofar Chuanshan Biological Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Beihai Gofar Chuanshan Biological Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Beihai Gofar Chuanshan Biological Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Beihai Gofar Chuanshan Biological Co., Ltd. Revenue
Year Revenue Growth
1999 64.182.107
2000 81.444.403 21.2%
2001 94.056.629 13.41%
2002 99.009.959 5%
2003 231.164.061 57.17%
2004 373.376.337 38.09%
2005 461.997.669 19.18%
2006 539.191.546 14.32%
2007 789.653.334 31.72%
2008 325.965.913 -142.25%
2009 241.318.529 -35.08%
2010 363.298.576 33.58%
2011 528.702.660 31.28%
2012 542.982.704 2.63%
2013 452.415.270 -20.02%
2014 415.412.217 -8.91%
2015 506.408.017 17.97%
2016 455.408.516 -11.2%
2017 434.487.818 -4.82%
2018 224.523.783 -93.52%
2019 251.153.525 10.6%
2020 267.699.833 6.18%
2021 424.717.057 36.97%
2022 459.684.048 7.61%
2023 356.053.529 -29.11%
2023 369.154.644 3.55%
2024 353.156.256 -4.53%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Beihai Gofar Chuanshan Biological Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.205.517 100%
2013 4.104.189 21.9%
2014 1.109.193 -270.02%
2015 1.065.162 -4.13%
2016 1.913.009 44.32%
2017 949.165 -101.55%
2018 250.319 -279.18%
2019 75.572 -231.23%
2020 50.133 -50.74%
2021 9.143.873 99.45%
2022 8.379.543 -9.12%
2023 8.038.046 -4.25%
2023 12.759.636 37%
2024 6.529.416 -95.42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Beihai Gofar Chuanshan Biological Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 11.666.883
2000 13.275.082 12.11%
2001 13.224.632 -0.38%
2002 13.429.131 1.52%
2003 37.671.140 64.35%
2004 37.404.197 -0.71%
2005 48.904.771 23.52%
2006 56.398.972 13.29%
2007 45.960.420 -22.71%
2008 38.510.762 -19.34%
2009 41.609.209 7.45%
2010 18.489.813 -125.04%
2011 16.134.398 -14.6%
2012 18.858.678 14.45%
2013 17.485.993 -7.85%
2014 24.016.233 27.19%
2015 16.256.348 -47.73%
2016 25.435.268 36.09%
2017 16.765.131 -51.72%
2018 11.090.022 -51.17%
2019 9.895.130 -12.08%
2020 12.486.889 20.76%
2021 16.968.150 26.41%
2022 17.094.177 0.74%
2023 111.846.069 84.72%
2023 20.219.401 -453.16%
2024 -18.433.579 209.69%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Beihai Gofar Chuanshan Biological Co., Ltd. EBITDA
Year EBITDA Growth
1999 22.453.911
2000 26.705.218 15.92%
2001 33.977.130 21.4%
2002 32.767.567 -3.69%
2003 46.961.403 30.22%
2004 61.417.494 23.54%
2005 88.047.307 30.24%
2006 58.850.834 -49.61%
2007 96.446.097 38.98%
2008 70.426.979 -36.94%
2009 44.957.937 -56.65%
2010 100.453.510 55.25%
2011 14.189.067 -607.96%
2012 6.776.304 -109.39%
2013 47.527.973 85.74%
2014 -11.827.478 501.84%
2015 44.491.616 126.58%
2016 -11.278.770 494.47%
2017 41.129.580 127.42%
2018 -3.836.427 1172.08%
2019 16.631.393 123.07%
2020 22.899.908 27.37%
2021 36.224.905 36.78%
2022 65.081.357 44.34%
2023 -24.544.998 365.15%
2023 -4.388.797 -459.26%
2024 10.715.880 140.96%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Beihai Gofar Chuanshan Biological Co., Ltd. Gross Profit
Year Gross Profit Growth
1999 43.643.910
2000 52.473.983 16.83%
2001 59.578.719 11.92%
2002 60.912.594 2.19%
2003 102.972.772 40.85%
2004 116.850.986 11.88%
2005 133.282.149 12.33%
2006 120.062.707 -11.01%
2007 178.636.444 32.79%
2008 30.640.722 -483%
2009 30.767.955 0.41%
2010 46.068.036 33.21%
2011 73.172.384 37.04%
2012 81.794.068 10.54%
2013 70.224.832 -16.47%
2014 45.529.701 -54.24%
2015 84.200.140 45.93%
2016 49.214.522 -71.09%
2017 79.262.911 37.91%
2018 44.380.974 -78.6%
2019 46.949.950 5.47%
2020 67.066.710 30%
2021 109.535.578 38.77%
2022 128.214.442 14.57%
2023 84.698.769 -51.38%
2023 91.697.473 7.63%
2024 89.187.756 -2.81%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Beihai Gofar Chuanshan Biological Co., Ltd. Net Profit
Year Net Profit Growth
1999 16.217.999
2000 15.608.025 -3.91%
2001 24.594.196 36.54%
2002 23.693.989 -3.8%
2003 28.093.746 15.66%
2004 16.207.110 -73.34%
2005 17.741.588 8.65%
2006 -30.215.324 158.72%
2007 3.035.071 1095.54%
2008 -176.709.758 101.72%
2009 -138.428.910 -27.65%
2010 16.403.146 943.92%
2011 -39.041.808 142.01%
2012 -109.567.462 64.37%
2013 10.688.527 1125.09%
2014 -49.195.977 121.73%
2015 4.053.060 1313.8%
2016 -31.861.949 112.72%
2017 8.850.641 460%
2018 -21.611.114 140.95%
2019 5.772.938 474.35%
2020 3.200.573 -80.37%
2021 10.486.532 69.48%
2022 34.841.980 69.9%
2023 -23.904.028 245.76%
2023 -82.308.270 70.96%
2024 -15.006.384 -448.49%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Beihai Gofar Chuanshan Biological Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 -1 0%
2009 -1 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Beihai Gofar Chuanshan Biological Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2001 19.643.072
2002 6.099.268 -222.06%
2003 -208.395.042 102.93%
2004 -333.838.207 37.58%
2005 -46.372.431 -619.91%
2006 77.204.392 160.06%
2007 -27.000.319 385.94%
2008 -3.992.727 -576.24%
2009 -12.239.775 67.38%
2010 -27.076.868 54.8%
2011 -28.187.080 3.94%
2012 -45.063.411 37.45%
2013 -26.289.661 -71.41%
2014 -94.375.124 72.14%
2015 -30.509.571 -209.33%
2016 -30.336.957 -0.57%
2017 20.860.662 245.43%
2018 -60.156.467 134.68%
2019 -9.945.242 -504.88%
2020 25.451.254 139.08%
2021 -29.632.666 185.89%
2022 -23.508.179 -26.05%
2023 -3.570.742 -558.36%
2023 -28.000.579 87.25%
2024 8.587.403 426.07%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Beihai Gofar Chuanshan Biological Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2001 23.347.464
2002 17.013.359 -37.23%
2003 -430.831 4048.97%
2004 5.940.014 107.25%
2005 2.935.350 -102.36%
2006 93.445.477 96.86%
2007 42.598.817 -119.36%
2008 17.335.060 -145.74%
2009 -2.201.725 887.34%
2010 -14.713.589 85.04%
2011 -15.949.664 7.75%
2012 -24.086.550 33.78%
2013 -4.948.439 -386.75%
2014 -41.047.746 87.94%
2015 -6.536.685 -527.96%
2016 -18.593.188 64.84%
2017 36.120.221 151.48%
2018 -33.751.596 207.02%
2019 -5.442.980 -520.09%
2020 26.844.785 120.28%
2021 -6.338.055 523.55%
2022 -15.741.512 59.74%
2023 0 0%
2023 -17.966.446 100%
2024 11.411.575 257.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Beihai Gofar Chuanshan Biological Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2001 3.704.392
2002 10.914.091 66.06%
2003 207.964.211 94.75%
2004 339.778.221 38.79%
2005 49.307.781 -589.1%
2006 16.241.085 -203.6%
2007 69.599.136 76.66%
2008 21.327.787 -226.33%
2009 10.038.051 -112.47%
2010 12.363.279 18.81%
2011 12.237.416 -1.03%
2012 20.976.861 41.66%
2013 21.341.222 1.71%
2014 53.327.378 59.98%
2015 23.972.887 -122.45%
2016 11.743.769 -104.13%
2017 15.259.558 23.04%
2018 26.404.871 42.21%
2019 4.502.262 -486.48%
2020 1.393.530 -223.08%
2021 23.294.610 94.02%
2022 7.766.667 -199.93%
2023 3.570.742 -117.51%
2023 10.034.133 64.41%
2024 2.824.172 -255.29%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Beihai Gofar Chuanshan Biological Co., Ltd. Equity
Year Equity Growth
1999 99.120.907
2000 105.481.924 6.03%
2001 130.150.510 18.95%
2002 147.533.574 11.78%
2003 478.863.037 69.19%
2004 522.139.479 8.29%
2005 551.302.233 5.29%
2006 529.385.257 -4.14%
2007 493.005.664 -7.38%
2008 320.947.642 -53.61%
2009 208.398.886 -54.01%
2010 225.469.051 7.57%
2011 191.611.623 -17.67%
2012 91.599.827 -109.18%
2013 111.530.626 17.87%
2014 729.586.512 84.71%
2015 737.836.216 1.12%
2016 688.785.032 -7.12%
2017 659.175.453 -4.49%
2018 637.564.339 -3.39%
2019 645.608.650 1.25%
2020 851.564.289 24.19%
2021 922.614.145 7.7%
2022 959.979.509 3.89%
2023 879.304.513 -9.17%
2023 946.154.397 7.07%
2024 864.454.083 -9.45%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Beihai Gofar Chuanshan Biological Co., Ltd. Assets
Year Assets Growth
1999 166.949.680
2000 195.977.577 14.81%
2001 206.656.094 5.17%
2002 235.219.459 12.14%
2003 740.206.200 68.22%
2004 1.045.188.190 29.18%
2005 1.267.654.937 17.55%
2006 1.301.114.775 2.57%
2007 1.308.200.304 0.54%
2008 1.207.207.438 -8.37%
2009 943.423.677 -27.96%
2010 706.756.670 -33.49%
2011 696.542.540 -1.47%
2012 613.977.379 -13.45%
2013 690.741.131 11.11%
2014 991.158.271 30.31%
2015 984.019.102 -0.73%
2016 957.710.480 -2.75%
2017 776.749.131 -23.3%
2018 763.381.653 -1.75%
2019 750.047.508 -1.78%
2020 1.065.713.192 29.62%
2021 1.082.774.790 1.58%
2022 1.142.144.892 5.2%
2023 1.055.520.704 -8.21%
2023 1.112.807.351 5.15%
2024 1.038.278.607 -7.18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Beihai Gofar Chuanshan Biological Co., Ltd. Liabilities
Year Liabilities Growth
1999 67.828.772
2000 90.495.651 25.05%
2001 76.505.583 -18.29%
2002 87.685.885 12.75%
2003 261.343.163 66.45%
2004 523.048.709 50.03%
2005 716.352.703 26.98%
2006 771.729.517 7.18%
2007 815.306.255 5.34%
2008 881.780.947 7.54%
2009 736.056.512 -19.8%
2010 481.287.618 -52.93%
2011 504.930.916 4.68%
2012 522.377.551 3.34%
2013 579.210.505 9.81%
2014 261.571.757 -121.43%
2015 246.182.885 -6.25%
2016 268.925.447 8.46%
2017 117.573.677 -128.73%
2018 125.817.314 6.55%
2019 104.438.857 -20.47%
2020 214.148.902 51.23%
2021 160.160.645 -33.71%
2022 182.165.382 12.08%
2023 176.216.189 -3.38%
2023 166.652.955 -5.74%
2024 173.824.523 4.13%

Beihai Gofar Chuanshan Biological Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.67
Net Income per Share
-0.17
Price to Earning Ratio
-22.82x
Price To Sales Ratio
5.77x
POCF Ratio
-487.11
PFCF Ratio
-138.47
Price to Book Ratio
2.37
EV to Sales
5.43
EV Over EBITDA
-74.46
EV to Operating CashFlow
-458.82
EV to FreeCashFlow
-130.43
Earnings Yield
-0.04
FreeCashFlow Yield
-0.01
Market Cap
2,02 Bil.
Enterprise Value
1,91 Bil.
Graham Number
2.49
Graham NetNet
0.42

Income Statement Metrics

Net Income per Share
-0.17
Income Quality
0.05
ROE
-0.1
Return On Assets
-0.09
Return On Capital Employed
-0.09
Net Income per EBT
1.09
EBT Per Ebit
0.99
Ebit per Revenue
-0.23
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.24
Operating Profit Margin
-0.23
Pretax Profit Margin
-0.23
Net Profit Margin
-0.25

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
-2.52
Capex to Revenue
0.03
Capex to Depreciation
4.17
Return on Invested Capital
-0.1
Return on Tangible Assets
-0.11
Days Sales Outstanding
291.05
Days Payables Outstanding
103.75
Days of Inventory on Hand
114.52
Receivables Turnover
1.25
Payables Turnover
3.52
Inventory Turnover
3.19
Capex per Share
0.02

Balance Sheet

Cash per Share
0,27
Book Value per Share
1,65
Tangible Book Value per Share
1.22
Shareholders Equity per Share
1.63
Interest Debt per Share
0.05
Debt to Equity
0.03
Debt to Assets
0.02
Net Debt to EBITDA
4.59
Current Ratio
3.09
Tangible Asset Value
0,64 Bil.
Net Current Asset Value
0,34 Bil.
Invested Capital
691293345
Working Capital
0,35 Bil.
Intangibles to Total Assets
0.22
Average Receivables
0,29 Bil.
Average Payables
0,08 Bil.
Average Inventory
82466534
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Beihai Gofar Chuanshan Biological Co., Ltd. Dividends
Year Dividends Growth
2003 0

Beihai Gofar Chuanshan Biological Co., Ltd. Profile

About Beihai Gofar Chuanshan Biological Co., Ltd.

Beihai Gofar Chuanshan Biological Co., Ltd. engages in the production and distribution of pharmaceutical products in China. The company offers various medicines and medical devices; and produces and sells pearl eyesight eye drops, gastrointestinal granules, pearl powder, and other proprietary Chinese medicines. It also provides molecular medical imaging and tumor radiotherapy centers, as well as tumor telemedicine technical services. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in May 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was founded in 1993 is based in Beihai, China.

CEO
Dr. Bin Pan Li
Employee
463
Address
No.3 Beibuwan Middle Road
Beihai, 536000

Beihai Gofar Chuanshan Biological Co., Ltd. Executives & BODs

Beihai Gofar Chuanshan Biological Co., Ltd. Executives & BODs
# Name Age
1 Dr. Bin Pan Li
Chairman & Chief Executive Officer
70
2 Mr. Yong Li
Secretary, Vice President & Director
70
3 Binbin Li
Accounting Supervisor
70
4 Mr. Zhi Bo Yin
Chief Financial Officer, Vice President & Director
70

Beihai Gofar Chuanshan Biological Co., Ltd. Competitors